{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:48:09Z","timestamp":1792784889517,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"MMRF Challenge Award"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01272-2","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T09:22:35Z","timestamp":1745486555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1\/CD138\/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide"],"prefix":"10.1038","volume":"15","author":[{"given":"Diana","family":"Cirstea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4350-9240","authenticated-orcid":false,"given":"Rajib","family":"Shome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9978-5682","authenticated-orcid":false,"given":"Mehmet","family":"Samur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikanth","family":"Talluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra Jean","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Duvallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda N. R.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Lively","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Basinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3623-7491","authenticated-orcid":false,"given":"Andrew J.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana Costa","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Niesvizky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-1275","authenticated-orcid":false,"given":"Noopur S.","family":"Raje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"1272_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u2013e48.","journal-title":"Lancet Oncol"},{"key":"1272_CR2","doi-asserted-by":"publisher","first-page":"8000","DOI":"10.1200\/JCO.2019.37.15_suppl.8000","volume":"37","author":"JS Miguel","year":"2019","unstructured":"Miguel JS, Mateos M-V, Gonzalez V, Dimopoulos MA, Kastritis E, Hajek R, et al. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. J Clin Oncol. 2019;37:8000.","journal-title":"J Clin Oncol"},{"key":"1272_CR3","doi-asserted-by":"publisher","first-page":"e183267","DOI":"10.1001\/jamaoncol.2018.3267","volume":"4","author":"AK Nooka","year":"2018","unstructured":"Nooka AK, Wang M, Yee AJ, Kaufman JL, Bae J, Peterkin D, et al. Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial. JAMA Oncol. 2018;4:e183267.","journal-title":"JAMA Oncol"},{"key":"1272_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/leu.2014.159","volume":"29","author":"J Bae","year":"2015","unstructured":"Bae J, Prabhala R, Voskertchian A, Brown A, Maguire C, Richardson P, et al. A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia. 2015;29:218\u201329.","journal-title":"Leukemia"},{"key":"1272_CR5","doi-asserted-by":"publisher","first-page":"6558","DOI":"10.18632\/oncotarget.2289","volume":"5","author":"M Kroesen","year":"2014","unstructured":"Kroesen M, Gielen P, Brok IC, Armandari I, Hoogerbrugge PM, Adema GJ. HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget. 2014;5:6558.","journal-title":"Oncotarget"},{"key":"1272_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Investig. 2014;124:30\u20139.","journal-title":"J Clin Investig"},{"key":"1272_CR7","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1073\/pnas.1011037108","volume":"108","author":"AJ Christiansen","year":"2011","unstructured":"Christiansen AJ, West A, Banks K-M, Haynes NM, Teng MW, Smyth MJ, et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci. 2011;108:4141\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"1272_CR8","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1182\/blood.V128.22.3307.3307","volume":"128","author":"R Niesvizky","year":"2016","unstructured":"Niesvizky R, Richardson PG, Yee AJ, Nooka AK, Raab MS, Shain KH, et al. Selective HDAC6 Inhibitor ACY-241, an Oral Tablet, Combined with Pomalidomide and Dexamethasone: Safety and Efficacy of Escalation and Expansion Cohorts in Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma (ACE-MM-200 Study). Blood. 2016;128:3307.","journal-title":"Blood"},{"key":"1272_CR9","doi-asserted-by":"crossref","unstructured":"San Miguel J, Mateos M-V, Gonzalez V, Dimopoulos MA, Kastritis E, Hajek R, et al. Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria. Am Soc Clin Onc. 2019;37:s8000.","DOI":"10.1200\/JCO.2019.37.15_suppl.8000"},{"key":"1272_CR10","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.4049\/jimmunol.168.4.1528","volume":"168","author":"KE Foulds","year":"2002","unstructured":"Foulds KE, Zenewicz LA, Shedlock DJ, Jiang J, Troy AE, Shen H. Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol. 2002;168:1528\u201332.","journal-title":"J Immunol"},{"key":"1272_CR11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3389\/fphar.2020.00971","volume":"11","author":"J Yang","year":"2020","unstructured":"Yang J, Li D, Zhou J. Histone Deacetylase 6 as a Therapeutic Target in B cell-associated Hematological Malignancies. Front Pharm. 2020;11:971.","journal-title":"Front Pharm"},{"key":"1272_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7838","volume":"6","author":"M Waibel","year":"2015","unstructured":"Waibel M, Christiansen AJ, Hibbs ML, Shortt J, Jones SA, Simpson I, et al. Manipulation of B-cell responses with histone deacetylase inhibitors. Nat Commun. 2015;6:6838.","journal-title":"Nat Commun"},{"key":"1272_CR13","doi-asserted-by":"publisher","first-page":"28096","DOI":"10.18632\/oncotarget.8581","volume":"7","author":"M Jourdan","year":"2016","unstructured":"Jourdan M, Cren M, Schafer P, Robert N, Duperray C, Vincent L, et al. Differential effects of lenalidomide during plasma cell differentiation. Oncotarget. 2016;7:28096\u2013111.","journal-title":"Oncotarget"},{"key":"1272_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.cell.2019.02.005","volume":"177","author":"M Binnewies","year":"2019","unstructured":"Binnewies M, Mujal AM, Pollack JL, Combes AJ, Hardison EA, Barry KC, et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4(+) T Cell Immunity. Cell. 2019;177:556\u201371.e16.","journal-title":"Cell"},{"key":"1272_CR15","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1182\/blood-2013-02-482513","volume":"122","author":"N Fiegler","year":"2013","unstructured":"Fiegler N, Textor S, Arnold A, R\u00f6lle A, Oehme I, Breuhahn K, et al. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood. 2013;122:684\u201393.","journal-title":"Blood"},{"key":"1272_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216121","volume":"559","author":"B Moran","year":"2023","unstructured":"Moran B, Davern M, Reynolds JV, Donlon NE, Lysaght J. The impact of histone deacetylase inhibitors on immune cells and implications for cancer therapy. Cancer Lett. 2023;559:216121.","journal-title":"Cancer Lett"},{"key":"1272_CR17","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s43018-023-00657-1","volume":"4","author":"F Maura","year":"2023","unstructured":"Maura F, Boyle EM, Coffey D, Maclachlan K, Gagler D, Diamond B, et al. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer. 2023;4:1660\u201374.","journal-title":"Nat Cancer"},{"key":"1272_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1411352","volume":"15","author":"P Abdollahi","year":"2024","unstructured":"Abdollahi P, Norseth HM, Schjesvold F. Advances and challenges in anti-cancer vaccines for multiple myeloma. Front Immunol. 2024;15:1411352.","journal-title":"Front Immunol"},{"key":"1272_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bbmt.2018.11.015","volume":"25","author":"M Bhutani","year":"2019","unstructured":"Bhutani M, Foureau D, Zhang Q, Robinson M, Wynn AS, Steuerwald NM, et al. Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma. Biol Blood Marrow Transplant. 2019;25:459\u201365.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1272_CR20","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","volume":"186","author":"L Ma","year":"2023","unstructured":"Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186:3148\u201365.e20.","journal-title":"Cell"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01272-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01272-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01272-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T09:22:40Z","timestamp":1745486560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01272-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1272"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01272-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"13 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Massachusetts General Hospital (16\u2013237). All methods were performed in accordance with the Declaration of Helsinki, the relevant guidelines, and regulations. Informed consent was obtained from all individual participants in this experiment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"77"}}